All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said.
News
Acupuncture can help ease the nausea and drowsiness that follows an autologous hematopoietic stem cell transplant in  multiple myeloma patients, a new study suggests. These symptoms…
A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The…
The Japanese Ministry of Health, Labor, and Welfare has approved Darzalex (daratumumab) in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib)…
Autolus has successfully completed dosing the first group of patients in a Phase 1/2 trial of AUTO2 — a CAR T-cell therapy that targets two…
The developers of the myeloma therapy candidate bb2121 have started an extension study of a Phase 1 clinical trial to continue evaluating its safety and…
The Phase 1b clinical trial called MUK eleven (NCT03015922) testing Reolysin (pelareorep) as a combination therapy for relapsing myeloma patients has dosed its first…
Based on recently published safety data, two clinical trials evaluating combinations of Tecentriq (atezolizumab) in multiple myeloma and follicular lymphoma patients were placed on partial clinical hold at…
Sellas Life Sciences’ cancer vaccine galinpepimut-S showed promising effects in patients with an aggressive form of multiple myeloma, researchers said in a presentation at…
The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy…
